2026 Q4 -tulosraportti
15 päivää sitten
‧37 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 7.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q4 -tulosraportti 15.6. | ||
2026 Q3 -tulosraportti 6.2. | ||
2026 Q2 -tulosraportti 7.11.2025 | ||
Ylimääräinen yhtiökokous 2025 10.10.2025 | ||
Vuosittainen yhtiökokous 2025 26.9.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·18.2. · MuokattuThis post is about Cantourage Group SE, which is the leading German player in the medical cannabis market in Germany/Europe – and the coverage I continuously provide of the company. The background is the recently announced transaction where Organigram Global Inc. acquires Sanity Group GmbH. The headline speaks for itself: ”Organigram to acquire Sanity Group for up-front consideration of €113.4 million plus a maximum earnout of up to €113.8 million tied to financial performance.” The press release can be read here: https://www.organigram.ca/_files/ugd/dad9ab_8cd368c0bdf540ef98a6f62780e15a38.pdf?utm_medium=social&utm_campaign=sanity The transaction involves an upfront payment of €113,4 million and a possible earnout of an additional €113,8 million, bringing the total potential payment to around €227 million. The official valuation table shows that the total potential valuation – including Organigram's existing ownership stake – can reach €250 million. Looking at Sanity's development, growth is as follows: from €9 million in revenue in 2023 to €60 million in 2025, including €19 million in the fourth quarter of 2025 alone. The gross margin has simultaneously improved from 15 % in 2023 to 47 % in 2025. The upfront valuation of €130 million corresponds, according to the announcement, to an LQA-multiple of 1,7x based on Q4 2025 annualized revenue, and the earnout model uses multiples of 1,75x revenue and 12,5x EBITDA. The interesting aspect – and the reason I bring it into the coverage of Cantourage – is the direct comparability. Cantourage delivered revenue of €74,9 million and an EBITDA of €3,9 million in the first nine months of 2025. The market capitalization is around €50 million. In other words: Cantourage generated more revenue in nine months than Sanity did in all of 2025, and yet Cantourage is traded at a market capitalization that is less than half of Sanity's upfront purchase price. Looking at the full earnout structure, the potential payment for Sanity corresponds to more than four times Cantourage's current market cap. This is not a question of comparing two identical companies point by point. It is a reference transaction in the same regulatory environment, the same geographical market, and the same overall value chain. Sanity is described as one of the leading players in Germany and is estimated to have a #2 market position as of January 2026, only surpassed by Cantourage Group. When an international strategic player is willing to pay up to €250 million for a German platform with €60 million in annual revenue and positive EBITDA, it serves as a concrete benchmark for the sector. The German medical cannabis market was estimated in the announcement to be over €2 billion in 2025 with an expectation of more than €4,5 billion in 2028. Consolidation is thus not theoretical – it is underway, and it is happening at multiples significantly above the listed peer valuations. For me, the transaction does not change the fundamentals of Cantourage. But it highlights the asymmetry that currently exists between private M&A pricing and the stock market's valuation. And precisely for this reason, it is relevant in the continued analysis of Cantourage. I maintain my assessment that there is still significant upside in the case around Cantourage Group SE. Looking in isolation at the recently announced transaction regarding Sanity Group GmbH as a reference point, the current valuation of Cantourage appears significantly low. If the market were to apply a similar transaction logic and relative multiples, it indicates, in my assessment, a share price in the range of €6,5–8,0 – potentially higher, if a strategic premium is included. This is, mind you, without adding further upside related to future performance, market shares, etc. The central point is not the precise price target, but the structural point: A concrete, comparable M&A reference has emerged in the same market, and it points to a significant gap between private transaction value and the stock market's current pricing of Cantourage. Disclaimer: I myself have a solid position in Cantourage Group (with entry at a price of €3,02).
18.12.2025An Executive Order coming today on cannabis! Huge day for the whole industry! https://www.marijuanamoment.net/white-house-confirms-trump-will-address-marijuana-rescheduling-tomorrow-but-reported-details-on-final-decision-are-speculation/https://rollcall.com/factbase/trump/topic/calendar/
22.12.2025 · MuokattuI don't understand why all these companies are just melting after this? Short term profit taking or massive short selling? Many of these companies rose sharply before this, so maybe something like that. At least I haven't seen any negative news lately.
12.12.2025Yeah, just over -98% anymore. 🥳😂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q4 -tulosraportti
15 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18.2. · MuokattuThis post is about Cantourage Group SE, which is the leading German player in the medical cannabis market in Germany/Europe – and the coverage I continuously provide of the company. The background is the recently announced transaction where Organigram Global Inc. acquires Sanity Group GmbH. The headline speaks for itself: ”Organigram to acquire Sanity Group for up-front consideration of €113.4 million plus a maximum earnout of up to €113.8 million tied to financial performance.” The press release can be read here: https://www.organigram.ca/_files/ugd/dad9ab_8cd368c0bdf540ef98a6f62780e15a38.pdf?utm_medium=social&utm_campaign=sanity The transaction involves an upfront payment of €113,4 million and a possible earnout of an additional €113,8 million, bringing the total potential payment to around €227 million. The official valuation table shows that the total potential valuation – including Organigram's existing ownership stake – can reach €250 million. Looking at Sanity's development, growth is as follows: from €9 million in revenue in 2023 to €60 million in 2025, including €19 million in the fourth quarter of 2025 alone. The gross margin has simultaneously improved from 15 % in 2023 to 47 % in 2025. The upfront valuation of €130 million corresponds, according to the announcement, to an LQA-multiple of 1,7x based on Q4 2025 annualized revenue, and the earnout model uses multiples of 1,75x revenue and 12,5x EBITDA. The interesting aspect – and the reason I bring it into the coverage of Cantourage – is the direct comparability. Cantourage delivered revenue of €74,9 million and an EBITDA of €3,9 million in the first nine months of 2025. The market capitalization is around €50 million. In other words: Cantourage generated more revenue in nine months than Sanity did in all of 2025, and yet Cantourage is traded at a market capitalization that is less than half of Sanity's upfront purchase price. Looking at the full earnout structure, the potential payment for Sanity corresponds to more than four times Cantourage's current market cap. This is not a question of comparing two identical companies point by point. It is a reference transaction in the same regulatory environment, the same geographical market, and the same overall value chain. Sanity is described as one of the leading players in Germany and is estimated to have a #2 market position as of January 2026, only surpassed by Cantourage Group. When an international strategic player is willing to pay up to €250 million for a German platform with €60 million in annual revenue and positive EBITDA, it serves as a concrete benchmark for the sector. The German medical cannabis market was estimated in the announcement to be over €2 billion in 2025 with an expectation of more than €4,5 billion in 2028. Consolidation is thus not theoretical – it is underway, and it is happening at multiples significantly above the listed peer valuations. For me, the transaction does not change the fundamentals of Cantourage. But it highlights the asymmetry that currently exists between private M&A pricing and the stock market's valuation. And precisely for this reason, it is relevant in the continued analysis of Cantourage. I maintain my assessment that there is still significant upside in the case around Cantourage Group SE. Looking in isolation at the recently announced transaction regarding Sanity Group GmbH as a reference point, the current valuation of Cantourage appears significantly low. If the market were to apply a similar transaction logic and relative multiples, it indicates, in my assessment, a share price in the range of €6,5–8,0 – potentially higher, if a strategic premium is included. This is, mind you, without adding further upside related to future performance, market shares, etc. The central point is not the precise price target, but the structural point: A concrete, comparable M&A reference has emerged in the same market, and it points to a significant gap between private transaction value and the stock market's current pricing of Cantourage. Disclaimer: I myself have a solid position in Cantourage Group (with entry at a price of €3,02).
- 18.12.2025An Executive Order coming today on cannabis! Huge day for the whole industry! https://www.marijuanamoment.net/white-house-confirms-trump-will-address-marijuana-rescheduling-tomorrow-but-reported-details-on-final-decision-are-speculation/https://rollcall.com/factbase/trump/topic/calendar/22.12.2025 · MuokattuI don't understand why all these companies are just melting after this? Short term profit taking or massive short selling? Many of these companies rose sharply before this, so maybe something like that. At least I haven't seen any negative news lately.
- 12.12.2025Yeah, just over -98% anymore. 🥳😂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 7.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q4 -tulosraportti 15.6. | ||
2026 Q3 -tulosraportti 6.2. | ||
2026 Q2 -tulosraportti 7.11.2025 | ||
Ylimääräinen yhtiökokous 2025 10.10.2025 | ||
Vuosittainen yhtiökokous 2025 26.9.2025 |
2026 Q4 -tulosraportti
15 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 7.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q4 -tulosraportti 15.6. | ||
2026 Q3 -tulosraportti 6.2. | ||
2026 Q2 -tulosraportti 7.11.2025 | ||
Ylimääräinen yhtiökokous 2025 10.10.2025 | ||
Vuosittainen yhtiökokous 2025 26.9.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18.2. · MuokattuThis post is about Cantourage Group SE, which is the leading German player in the medical cannabis market in Germany/Europe – and the coverage I continuously provide of the company. The background is the recently announced transaction where Organigram Global Inc. acquires Sanity Group GmbH. The headline speaks for itself: ”Organigram to acquire Sanity Group for up-front consideration of €113.4 million plus a maximum earnout of up to €113.8 million tied to financial performance.” The press release can be read here: https://www.organigram.ca/_files/ugd/dad9ab_8cd368c0bdf540ef98a6f62780e15a38.pdf?utm_medium=social&utm_campaign=sanity The transaction involves an upfront payment of €113,4 million and a possible earnout of an additional €113,8 million, bringing the total potential payment to around €227 million. The official valuation table shows that the total potential valuation – including Organigram's existing ownership stake – can reach €250 million. Looking at Sanity's development, growth is as follows: from €9 million in revenue in 2023 to €60 million in 2025, including €19 million in the fourth quarter of 2025 alone. The gross margin has simultaneously improved from 15 % in 2023 to 47 % in 2025. The upfront valuation of €130 million corresponds, according to the announcement, to an LQA-multiple of 1,7x based on Q4 2025 annualized revenue, and the earnout model uses multiples of 1,75x revenue and 12,5x EBITDA. The interesting aspect – and the reason I bring it into the coverage of Cantourage – is the direct comparability. Cantourage delivered revenue of €74,9 million and an EBITDA of €3,9 million in the first nine months of 2025. The market capitalization is around €50 million. In other words: Cantourage generated more revenue in nine months than Sanity did in all of 2025, and yet Cantourage is traded at a market capitalization that is less than half of Sanity's upfront purchase price. Looking at the full earnout structure, the potential payment for Sanity corresponds to more than four times Cantourage's current market cap. This is not a question of comparing two identical companies point by point. It is a reference transaction in the same regulatory environment, the same geographical market, and the same overall value chain. Sanity is described as one of the leading players in Germany and is estimated to have a #2 market position as of January 2026, only surpassed by Cantourage Group. When an international strategic player is willing to pay up to €250 million for a German platform with €60 million in annual revenue and positive EBITDA, it serves as a concrete benchmark for the sector. The German medical cannabis market was estimated in the announcement to be over €2 billion in 2025 with an expectation of more than €4,5 billion in 2028. Consolidation is thus not theoretical – it is underway, and it is happening at multiples significantly above the listed peer valuations. For me, the transaction does not change the fundamentals of Cantourage. But it highlights the asymmetry that currently exists between private M&A pricing and the stock market's valuation. And precisely for this reason, it is relevant in the continued analysis of Cantourage. I maintain my assessment that there is still significant upside in the case around Cantourage Group SE. Looking in isolation at the recently announced transaction regarding Sanity Group GmbH as a reference point, the current valuation of Cantourage appears significantly low. If the market were to apply a similar transaction logic and relative multiples, it indicates, in my assessment, a share price in the range of €6,5–8,0 – potentially higher, if a strategic premium is included. This is, mind you, without adding further upside related to future performance, market shares, etc. The central point is not the precise price target, but the structural point: A concrete, comparable M&A reference has emerged in the same market, and it points to a significant gap between private transaction value and the stock market's current pricing of Cantourage. Disclaimer: I myself have a solid position in Cantourage Group (with entry at a price of €3,02).
- 18.12.2025An Executive Order coming today on cannabis! Huge day for the whole industry! https://www.marijuanamoment.net/white-house-confirms-trump-will-address-marijuana-rescheduling-tomorrow-but-reported-details-on-final-decision-are-speculation/https://rollcall.com/factbase/trump/topic/calendar/22.12.2025 · MuokattuI don't understand why all these companies are just melting after this? Short term profit taking or massive short selling? Many of these companies rose sharply before this, so maybe something like that. At least I haven't seen any negative news lately.
- 12.12.2025Yeah, just over -98% anymore. 🥳😂
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt